Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Retinoic acid and its analogs are used to treat tumors caused by tsc1/tsc2 inactivation or activation of its upstream pathway

A technology of retinoic acid and analogues, applied in the direction of antineoplastic drugs, drug combinations, active ingredients of hydroxyl compounds, etc., can solve problems such as unsatisfactory treatment conditions

Inactive Publication Date: 2011-12-21
THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the current treatment situation is not ideal, and most of them are accompanied by serious side effects (28,29)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Retinoic acid and its analogs are used to treat tumors caused by tsc1/tsc2 inactivation or activation of its upstream pathway
  • Retinoic acid and its analogs are used to treat tumors caused by tsc1/tsc2 inactivation or activation of its upstream pathway
  • Retinoic acid and its analogs are used to treat tumors caused by tsc1/tsc2 inactivation or activation of its upstream pathway

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0088] 1. Experimental materials:

[0089] 1) Reagent

[0090] A. Reagents related to bacterial culture:

[0091] Yeast powder, tryptone, agar powder (OXOID company); ampicillin (Beijing Dingguo Biotechnology Co., Ltd.).

[0092] B. Reagents related to cell culture:

[0093] DMEM medium, fetal bovine serum (GibcoBRL company);

[0094] Penicillin, streptomycin (North China Pharmaceutical Co., Ltd.);

[0095] 5-Aza-dC, TSA, retinoic acid (RA), trypsin, rapamycin, PI, DAPT, CompoundE, hygromycin (Sigma);

[0096] Lipofectamin2000 (Invitrogen Corporation).

[0097] C. Reagents for gene cloning and real-time quantitative PCR:

[0098] DNA High Fidelity Polymerase PfuUltra TM High-Fidelity (Stratagene);

[0099] Restriction enzymes ClaI, HpaI, BamHI, XhoI, T4 DNA ligase, PrimeScript TM RT Reagent Kit (TaKaRa Corporation);

[0100] 1kb DNA Ladder, DL2000 (Tiangen Biological Co., Ltd.);

[0101] GoldView TM (GV) nucleic acid dye, agarose (Saibaisheng biological company); ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides the use of retinoic acid and its analogs in the preparation of medicines for treating mammals including human tumors caused by TSC1 / TSC2 inactivation or activation of its upstream pathway. The invention also provides retinoic acid and its analogs and mTOR Use of the pharmaceutical composition composed of pathway inhibitors in the preparation of medicines for treating tumors in mammals including humans caused by TSC1 / TSC2 inactivation or activation of upstream pathways. The invention provides a new approach for the treatment of tumors caused by TSC1 / TSC2 inactivation.

Description

technical field [0001] The present invention relates to the use of retinoic acid and analogs thereof in the preparation of medicines for treating tumors in mammals including humans caused by inactivation of tuberous sclerosis complex genes 1 and 2 (TSC1 / TSC2) or activation of upstream pathways, The present invention also relates to the pharmaceutical composition composed of retinoic acid and its analogues and mammalian target of rapamycin (mTOR) pathway inhibitors for the treatment of tuberous sclerosis gene 1 and 2 (TSC1 / TSC2) inactivation or Use in medicine for tumors in mammals including humans resulting from upstream pathway activation. Background technique [0002] Tuberous Sclerosis Complex genes 1 and 2 (TSC1 and TSC2) are important tumor suppressor genes, and their protein products form a complex, mainly by controlling the activity of mTOR (Gene ID: 2475) to affect Protein synthesis and autophagy levels, thereby regulating cell growth and survival (1-8). mTOR is a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/203A61K31/436A61P35/00A61P35/02A61P17/00
Inventor 张宏冰查晓军
Owner THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com